deCODE Receives California Clinical Laboratory License
News Feb 24, 2009
deCODE genetics has announced that it has received a clinical laboratory license from the State of California. The quality and scale of deCODE’s in-house, CLIA-registered genotyping laboratory underpins deCODE’s global leadership in the discovery of variations in the sequence of the human genome conferring risk of common diseases.
The same staff and facility also process deCODE’s DNA-based reference laboratory tests for gauging individual risk of major public health challenges ranging from heart attack to breast cancer, as well as the company’s deCODEme™ scans. The company says that with this license, California residents can now benefit from the unrivalled quality of deCODE products for understanding risk and, working with their physicians, empowering the prevention of common diseases.
Through its reference laboratory testing service, www.decodediagnostics.com, deCODE offers DNA-based tests for assessing individual risk of heart attack, type 2 diabetes, stroke, breast cancer, prostate cancer, and glaucoma.
deCODEme™ is said to be the world’s first retail genome analysis service, available at www.decodeme.com. The full genome Complete Scan scan and the Cardio and Cancer scans build on deCODE’s discovery of common variations in the sequence of the human genome conferring increased risk of common diseases.
Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.